WCLC26 Highlights
🔹EGFR: Adjuvant #osimertinib → 74% 8-year OS in stage II-IIIA disease
🔹ROS1+: #Zidesamtinib → 94% response rate with strong intracranial activity
🔹HER2: T-DXd → improved PFS, but pulmonary safety remains a concern
🔹EGFR exon 20ins: #Amivantamab + chemotherapy → 34.3-month median OS

PAPILLON Study Reveals Promising Survival Rates for Advanced NSCLC with Amivantamab #Seoul #NSCLC #Amivantamab #PAPILLON #Republic_of_Korea